1,010 results on '"Mastocytosis, Systemic"'
Search Results
2. A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
3. (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
4. Avapritinib With Decitabine in Patients With SM-AHN
5. (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
6. (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
7. (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
8. Managed Access Programs for PKC412, Midostaurin
9. Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
10. Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis
11. Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis (DenosuMast)
12. Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE)
13. Angioedema Biomarker Research Study
14. Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
15. A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
16. Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
17. A Registry for Patients With Systemic Mastocytosis in China
18. Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia
19. Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
20. Evaluation of the DALY on a Cohort of Patients With Indolent Systemic Mastocytosis (DALY-MAST)
21. Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
22. (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
23. GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
24. Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
25. Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients (HCQMa)
26. A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
27. Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
28. Use of Tamoxifen in Systemic Mastocytosis
29. Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis (AB06006)
30. Adaptation of the Questionnaire 'Regarding Patient's Quality of Life With Mastocytosis' in the French Language (Mc_QoL)
31. Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis (EvaTryMS)
32. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
33. Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
34. Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
35. Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
36. Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
37. Dental management of a patient with systemic mastocytosis
38. Stem Cell Transplantation to Treat Systemic Mastocytosis
39. Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
40. Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
41. Treatment of Indolent Systemic Mastocytosis With PA101
42. Imatinib in KIT-negative Systemic Mastocytosis
43. Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
44. Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
45. Midostaurin in Indolent Systemic Mastocytosis
46. Cladribine improves cutaneous manifestations, Dermatology Life Quality Index, and Mastocytosis Quality of Life of patients with mastocytosis.
47. KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine.
48. How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms
49. Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis
50. Therapeutic management and outcome of patients with advanced systemic mastocytosis treated with midostaurin: A comprehensive real‐life study in the French national healthcare database
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.